Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.

被引：0

作者：

Chaft, Jamie E.

Costa, Daniel Botelho

Muzikansky, Alona

Shrager, Joseph B.

Lanuti, Michael

Huang, James

Ramchandran, Kavitha

Rangachari, Deepa

Huberman, Mark

Piotrowska, Zofia

Kris, Mark G.

Azzoli, Christopher G.

Sequist, Lecia V.

Neal, Joel W.

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Stanford Canc Inst, Stanford, CA USA

[6] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA

[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[8] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[9] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[10] Harvard Med Sch, Boston, MA 02115 USA

[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[12] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[13] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

[14] Stanford Univ, Stanford, CA 94305 USA

[15] Stanford Canc Inst, Stanford, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8507

引用

页数：2

共 50 条

[31] MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
Therasse, P.
Vansteenkiste, J. F.
Zielinski, M.
De Pas, T. M.
Atanackovic, D.
Sequist, L. V.
Vallieres, E.
Swisher, S.
Adams, S.
Passlick, B.
Eberhardt, W. E. E.
Grunenwald, D.
Mok, T.
Boyer, M.
Katz, A.
Douillard, J.
Debois, M.
Brichard, V. G.
Altorki, N. K.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[32] Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin and chemoradiation in stage III NSCLC. SLCG 10/02.
Provencio-Pulla, Mariano
De Las Penas, Ramon
Banaclocha, Natividad Martinez
Fabregat, Raquel Marse
Insa, Amelia
Moran, Teresa
Sala Gonzalez, Maria Angeles
Massuti, Bartomeu
Mut Sanchis, Pilar
Ortega Granados, Ana Laura
Miguel Jurado, Jose
Gomez-Codina, Jose
Artal-Cortes, Angel
Francisca Vazquez, Maria
Gutierrez Calderon, Vanesa
Diz, Pilar
Vinolas, Nuria
Maestu, Inmaculada
Camps, Carlos
Isla, Dolores
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma (I-MAT Trial)
Xu, W.
Poulsen, M.
Atkinson, V.
Fogarty, G.
Veness, M.
Smithers, B.
Gyorki, D.
Mar, V.
Howle, J.
Guminski, A.
Williams, N.
Paton, E.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 137 - 137
[34] Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial
Wang, Si-Yu
Long, Hao
Li, Ning
Cheng, Chao
Ou, Wei
Yang, Lin
You, Jian
Liang, Yi
Wang, Bao-Xiao
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[35] Adjuvant Osimertinib vs Placebo in Completely Resected Stage IA2-IA3 EGFR-mutated NSCLC: The ADAURA2 Phase III Study
Goldman, J.
Tsutani, Y.
Dacic, S.
Yatabe, Y.
Majem, M.
Huang, X.
Chen, A.
Van der Gronde, T.
He, J.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S103 - S104
[36] Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
Makoto Sonobe
Ken-ichi Okubo
Satoshi Teramukai
Kazuhiro Yanagihara
Masaaki Sato
Toshihiko Sato
Fengshi Chen
Kiyoshi Sato
Takuji Fujinaga
Tsuyoshi Shoji
Mitsugu Omasa
Hiroaki Sakai
Ryo Miyahara
Toru Bando
Hiroshi Date
Cancer Chemotherapy and Pharmacology, 2014, 74 : 1199 - 1206
[37] Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
Sonobe, Makoto
Okubo, Ken-ichi
Teramukai, Satoshi
Yanagihara, Kazuhiro
Sato, Masaaki
Sato, Toshihiko
Chen, Fengshi
Sato, Kiyoshi
Fujinaga, Takuji
Shoji, Tsuyoshi
Omasa, Mitsugu
Sakai, Hiroaki
Miyahara, Ryo
Bando, Toru
Date, Hiroshi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) : 1199 - 1206
[38] Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
Zhang, Shu-Ling
Yi, Xiao-Fang
Huang, Le-Tian
Sun, Li
Ma, Jie-Tao
Han, Cheng-Bo
BMC CANCER, 2023, 23 (01)
[39] Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
Shu-Ling Zhang
Xiao-Fang Yi
Le-Tian Huang
Li Sun
Jie-Tao Ma
Cheng-Bo Han
BMC Cancer, 23
[40] Prospective Phase I/II Study of Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC
Liveringhouse, C.
Lam, N. B.
Rosenberg, S. A.
Dilling, T. J.
Macmillan, G.
Chiappori, A.
Haura, E. B.
Creelan, B.
Gray, J.
Tanvetyanon, T.
Shafique, M.
Saltos, A. N.
Weiner, A. A.
Kelsey, C. R.
Schell, M.
Antonia, S. J.
Perez, B. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S3 - S4

← 1 2 3 4 5 →